menu
    • menu
    [{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Engineered Hematopoietic Stem Cell","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Engineered Hematopoietic Stem Cell","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Akron Biotech","sponsor":"Vor Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Engineered Human Stem Cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akron Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Akron Biotech \/ Vor Bio","highestDevelopmentStatusID":"7","companyTruncated":"Akron Biotech \/ Vor Bio"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Engineered Human Stem Cell Therapy","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Engineered Hematopoietic Stem Cell","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Engineered Hematopoietic Stem Cell","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Evercore Group L.L.C.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Gemtuzumab Ozogamicin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Evercore Group L.L.C.","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Evercore Group L.L.C."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Private Placement","leadProduct":"Gemtuzumab Ozogamicin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ RA Capital Management"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Ozogamicin

    Menu

    Ozogamicin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tremtelectogene Empogeditemcel,Ozogamicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First AML Patient Transplanted with Vor Bio Trem-cel Demonstrated Durable Engraftment Through Multiple Mylotar...

                            Details : Trem-cel (tremtelectogene empogeditemcel), is a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate in order to remove the CD33 surface target protecting them from a targeted therapy post-transplant.

                            Brand Name : Trem-cel

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 16, 2023

                            Lead Product(s) : Tremtelectogene Empogeditemcel,Ozogamicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trem-cel,Ozogamicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

                            Details : VOR33 (trem-cel) is our lead eHSC product candidate created by genetically modifying healthy donor HSCs in order to remove the CD33 surface target which is involved in causing AML and other blood related cancers thus, protecting them from a targeted ther...

                            Brand Name : VOR33

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 19, 2023

                            Lead Product(s) : Trem-cel,Ozogamicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tremtelectogene Empogeditemcel,Ozogamicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Evercore Group L.L.C.

                            Deal Size : $65.8 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds o...

                            Details : Vor Bio intends to use the net proceeds from the offering and concurrent private placement primarily to fund the continued clinical development of Trem-cel (tremtelectogene empogeditemcel) and pipeline products and for working capital and general corpora...

                            Brand Name : Trem-cel

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 07, 2022

                            Lead Product(s) : Tremtelectogene Empogeditemcel,Ozogamicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Evercore Group L.L.C.

                            Deal Size : $65.8 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tremtelectogene Empogeditemcel,Ozogamicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : RA Capital Management

                            Deal Size : $50.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds o...

                            Details : Vor Bio intends to use the net proceeds from the offering and concurrent private placement primarily to fund the continued clinical development of Trem-cel (Tremtelectogene Empogeditemcel) and pipeline products and for working capital and general corpora...

                            Brand Name : Trem-cel

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 07, 2022

                            Lead Product(s) : Tremtelectogene Empogeditemcel,Ozogamicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : RA Capital Management

                            Deal Size : $50.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tremtelectogene Empogeditemcel,Ozogamicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated My...

                            Details : Tremtelectogene empogeditemcel (trem-cel), formerly VOR33, is a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate where CD33 has been deleted using genome engineering.

                            Brand Name : VOR33

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 07, 2022

                            Lead Product(s) : Tremtelectogene Empogeditemcel,Ozogamicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered Hematopoietic Stem Cell,Ozogamicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-g...

                            Details : VOR33 (Engineered Hematopoietic Stem Cell) is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein.

                            Brand Name : VOR33

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 11, 2022

                            Lead Product(s) : Engineered Hematopoietic Stem Cell,Ozogamicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered Hematopoietic Stem Cell,Ozogamicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatm...

                            Details : The pre-clinical data of VOR33 (Engineered Hematopoietic Stem Cell), demonstrates that multiplex deletion by CRISPR/Cas9 of CD33 and CLL-1 from human CD34+ HSPCs maintained cell function and persisted long-term post engraftment in vivo.

                            Brand Name : VOR33

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 10, 2022

                            Lead Product(s) : Engineered Hematopoietic Stem Cell,Ozogamicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered Human Stem Cell Therapy,Ozogamicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting

                            Details : The data demonstrated Vor Bio’s novel platform, VOR33, genetically modifies healthy donor hematopoietic stem cells (HSCs) to remove select cell surface targets, enables targeted therapies to selectively destroy cancer cells while sparing the healthy ce...

                            Brand Name : VOR33

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 25, 2022

                            Lead Product(s) : Engineered Human Stem Cell Therapy,Ozogamicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Akron Biotech

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Akron Biotech

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered Human Stem Cell Therapy,Ozogamicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Vor Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases

                            Details : This collaboration strengthens Akron’s portfolio of off-the-shelf gene editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene modified cell therapies including VOR33.

                            Brand Name : VOR33

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 22, 2022

                            Lead Product(s) : Engineered Human Stem Cell Therapy,Ozogamicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Vor Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vor Biopharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered Hematopoietic Stem Cell,Ozogamicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT

                            Details : VOR33 is leads novel engineered hematopoietic stem cell (eHSC) product candidate designed to replace the standard of care in transplant settings and used in the treatment of Acute myeloid leukaemia designed to protect patients’ healthy cells from anti-...

                            Brand Name : VOR33

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 19, 2021

                            Lead Product(s) : Engineered Hematopoietic Stem Cell,Ozogamicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth